Bionor Pharma Announces Filing of International Patent Application for its HIV Vaccine Vacc-HIV

Oslo, 11.06.2013 – Bionor Pharma ASA (OSE: BIONOR) announced today that it has filed an International Patent Application for its HIV Vaccine, Vacc-HIV. This application gives Bionor Pharma the opportunity to obtain patent protection for Vacc-HIV in all the major international pharmaceutical markets. Vacc-HIV, which is currently in the preclinical stage of development, is a …

Read more

Patient Enrollment Completed in Bionor Pharma’s First Human Clinical Study of the HIV Vaccine Vacc-C5

Oslo 27.05.2013 – Bionor Pharma ASA (OSE: BIONOR) announced today that patient enrollment in the first clinical study of its second HIV vaccine, Vacc-C5, is now completed, with 36 HIV infected patients enrolled at Oslo University Hospital. Thirty six HIV Patients Participate at Oslo University Hospital Vacc-C5 has been developed with the aim to induce …

Read more

Last Patient Enrolled in Bionor Pharma’s International Study to Reboost Patients from the Completed Vacc-4x Phase II Clinical Trial

Oslo 29.04.2013 – Bionor Pharma ASA (OSE: BIONOR) announced today that all patients are now enrolled in the study for reboost of patients from the previously conducted phase II clinical study with Vacc-4x. Thirty-three Patients Participate at 10 Clinics in USA and Europe  The 33 patients are recruited at 10 clinics in USA, Germany, England, …

Read more